ADC Therapeutics: Continues To Make Strides With ZYNLONTA Targeting DLBCL (NYSE:ADCT)
This text was written byComply withTerry Chrisomalis is a non-public investor within the Biotech sector with years of expertise using ...
Tag: Therapeutics
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO | AlphaStreet
Depth Therapeutics, Inc. (NASDAQ: INTS) is a medical biotechnology firm engaged within the discovery improvement, and commercialization of first-in-class most ...
Cero Therapeutics announces CFO transition By Investing.com
Cero Therapeutics Holdings, Inc. (NASDAQ:CERO), a biotechnology firm specializing in organic merchandise, introduced the upcoming departure of Chief Monetary Officer ...
Stocks making the biggest moves midday: Ford, Viking Therapeutics, ServiceNow and more
Take a look at the businesses making headlines in noon buying and selling: Ford Motor — The automaker's inventory fell ...
Applied Therapeutics: Navigating Challenges In ARI Development
Klaus Vedfelt Govorestat’s Race Towards Galactose: A Candy or Bitter Future? Utilized Therapeutics (NASDAQ:APLT) is a clinical-stage biotech firm growing ...
Buying Esperion Therapeutics Despite An Abiding Skepticism Weighing On The Stock (ESPR)
Ariel Skelley/DigitalVision through Getty Pictures President and CEO of Esperion Therapeutics, Inc. (NASDAQ:ESPR), Sheldon Koenig, promised that the corporate would ...
Check Out What Whales Are Doing With VKTX – Viking Therapeutics (NASDAQ:VKTX)
Whales with some huge cash to spend have taken a noticeably bullish stance on Viking Therapeutics. choices historical past for ...
Akari Therapeutics secures $1.6M in private placement By Investing.com
© Reuters. In a strategic transfer, Akari Therapeutics (NASDAQ: NASDAQ:) has introduced right now a non-public placement settlement with choose ...
Aquestive Therapeutics stock target raised to $8 on FDA hopes By Investing.com
© Reuters. On Wednesday, Lake Road Capital Markets adjusted its outlook on Aquestive Therapeutics (NASDAQ:), a pharmaceutical firm, by growing ...
Morgan Stanley sets $40 target on Kyverna Therapeutics shares By Investing.com
© Reuters. On Monday, Morgan Stanley initiated protection on Kyverna Therapeutics Inc (NASDAQ:KYTX), a biopharmaceutical firm, with an Chubby ranking ...